Company Profile
Molecular Partners Stock Price, News & Catalysts
- Ticker:
- MOLN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Switzerland
Stock performance
3.21 USD (-0.98%)
Close
Last updated: November 5, 2026
147M USD
Market cap
Why the stock is moving
As of Nov 5, 2026, MOLN closed down 0.98% at $3.21. No new same-company headline was identified in the current news window.
Company overview
DARPin Therapeutics Platform
Molecular Partners develops multi-specific protein medicines based on Designed Ankyrin Repeat Proteins, compact binding molecules that can be engineered for high affinity and modularity.
Radio-DARPins
The company is attaching therapeutic radioisotopes to DARPins to deliver radiation selectively to tumor targets while retaining flexibility across isotope payloads.
MP0712
MP0712 targets DLL3 and is being evaluated in small cell lung cancer and other DLL3-expressing neuroendocrine tumors.
Next-Generation Radiotherapy Pipeline
Molecular Partners is developing additional Radio-DARPins, including multispecific constructs and programs using different alpha-emitting isotopes. MP0714 extends the DLL3 strategy into an early-access imaging and treatment program while the company builds candidates for additional tumor targets.
Future catalysts
- Initial safety data from the Phase 1/2a MP0712 study at the North America Conference on Lung Cancer in December 2026.
- Initial efficacy data from the Phase 1/2a MP0712 study in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Molecular Partners (MOLN)?
Molecular Partners (MOLN) most recently closed at 3.21 USD, a -0.98% move versus the previous session.
What is the market cap of Molecular Partners (MOLN)?
Molecular Partners currently has a market capitalization of 147M USD on BioPharmSignal.
What does Molecular Partners do?
DARPin Therapeutics Platform Molecular Partners develops multi-specific protein medicines based on Designed Ankyrin Repeat Proteins, compact binding molecules that can be engineered for high affinity and modularity. Radio-DARPins The company is attaching therapeutic radioisotopes to DARPins to deliver radiation selectively to tumor targets while retaining...
On which exchange is MOLN stock listed?
Molecular Partners (MOLN) is associated with NASDAQ, Switzerland, Biopharma.
What is DARPin?
DARPin Therapeutics Platform Molecular Partners develops multi-specific protein medicines based on Designed Ankyrin Repeat Proteins, compact binding molecules that can be engineered for high affinity and modularity.
Which conditions is Molecular Partners targeting with DARPin?
Molecular Partners is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Molecular Partners describe recent progress with DARPin?
Initial safety data from the Phase 1/2a MP0712 study at the North America Conference on Lung Cancer in December 2026. Initial efficacy data from the Phase 1/2a MP0712 study in 2027.
What is Therapeutics?
DARPin Therapeutics Platform Molecular Partners develops multi-specific protein medicines based on Designed Ankyrin Repeat Proteins, compact binding molecules that can be engineered for high affinity and modularity.